PCSK9 inhibitors for high cholesterol and heart disease
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study looks at how well two cholesterol-lowering medicines, evolocumab and alirocumab, work in people with high cholesterol or heart disease. It reviews medical records from patients at a specific hospital to see how these medicines affect cholesterol levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have high cholesterol or heart disease
- You started taking evolocumab or alirocumab between 2018 and 2024
- You have had your cholesterol checked within 6 months before starting the medicine and at least once after starting
- You are being followed by the cardiology department at Fundación Santa Fe de Bogotá
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two newer cholesterol-lowering medications (inclisiran and alirocumab) together in people who've had heart problems or strokes and cannot tolerate standard cholesterol drugs. The goal is to see if this combination safely lowers cholesterol further and reduces future cardiovascular events.
This trial compares two very low LDL-cholesterol targets (below 1.0 vs 1.0-1.39 mmol/L) using extra medications (PCSK9 inhibitors) to see which is safer and better for people at extremely high risk of heart attacks or strokes.
This trial studies whether lowering LDL (“bad cholesterol”) with a PCSK-9 inhibitor (evolocumab) improves blood flow to the heart, measured by special PET scans. It’s for people over a certain age who have stable coronary artery disease and a higher risk of heart problems.
This study tests whether starting evolocumab (a cholesterol-lowering injection) soon after a heart attack helps prevent future heart problems. You'll receive the study drug or placebo for 52 weeks while your heart is monitored with imaging scans.
This study follows people who are already taking PCSK9 inhibitor shots to see how well patients stay on treatment and how effective it is. Your participation would mainly be about consenting to provide basic information and possibly follow-up details.
This study tests whether evolocumab, a monthly injection, can shrink the fatty buildup (plaque) in your heart arteries. It is for people who have early signs of heart disease or diabetes but have not had a heart attack or stroke yet.
Hear when a new Hyperlipidemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.